



PATENT
Customer No. 22,852
Attorney Docket No. 4012.0373-01000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
R. W. Esmond et al.) Group Art Unit: 1614
)
Application No.: 10/669,281) Examiner: Vickie Y. Kim
)
Filed: September 23, 2003)
)
For: METHOD FOR TREATING OR)
PREVENTING ALZHEIMER'S DISEASE)

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the document listed on the attached Form PTO 1449. The reference listed thereon was previously submitted in the instant application to the Office on December 19, 2003, but lacking a publication date, the reference was not considered. The listing now includes the publication date.

A copy of the listed document was previously submitted in a prior application, Application No. 09/394,712, filed September 13, 1999, upon which Applicants rely for the benefits provided in 35 U.S.C. § 120. Applicants respectfully request that the Examiner consider the listed document and indicate that it was considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed document is material or constitutes "prior art." If the Examiner applies the document as prior art against any claim in the application and Applicants determine that the cited document does not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed document, should the document be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.


Dated: December 21, 2004

By: 
Lauren L. Stevens
Reg. No. 48,916
Customer No. 22,852

INFORMATION DISCLOSURE CITATION

OMB No. 0651-0011

Atty. Docket No.	4012.0373-01000	Appln. No.	10/669,281
Applicant	R. W. ESMOND et al.		
Filing Date	September 23, 2003	Group:	Not Yet Assigned



U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Arbeeny, C.M., "Novel Drug Development Strategies for the Treatment of Insulin Resistance," Drug & Market Dev. 9:204-209, 1998

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce